These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33822841)

  • 1. Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy.
    Loe AKH; Francis R; Seo J; Du L; Wang Y; Kim JE; Hakim SW; Kim JE; He HH; Guo H; Kim TH
    J Exp Med; 2021 Jun; 218(6):. PubMed ID: 33822841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation.
    Kase K; Saito M; Nakajima S; Takayanagi D; Saito K; Yamada L; Ashizawa M; Nakano H; Hanayama H; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Shiraishi K; Kohno T; Kono K
    Carcinogenesis; 2021 Feb; 42(1):21-30. PubMed ID: 33196828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
    Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
    PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
    Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
    Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.
    Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Bhat SA
    Pathol Oncol Res; 2021; 27():1609826. PubMed ID: 34924820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-host interactions in carcinogenesis of Epstein-Barr virus-associated gastric carcinoma: Potential roles of lost ARID1A expression in its early stage.
    Abe H; Kunita A; Otake Y; Kanda T; Kaneda A; Ushiku T; Fukayama M
    PLoS One; 2021; 16(9):e0256440. PubMed ID: 34469459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of ARID1A negative expression in gastric cancer.
    Ashizawa M; Saito M; Min AKT; Ujiie D; Saito K; Sato T; Kikuchi T; Okayama H; Fujita S; Endo H; Sakamoto W; Momma T; Ohki S; Goto A; Kono K
    Sci Rep; 2019 May; 9(1):6769. PubMed ID: 31043675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
    Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
    Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.
    Abe H; Maeda D; Hino R; Otake Y; Isogai M; Ushiku AS; Matsusaka K; Kunita A; Ushiku T; Uozaki H; Tateishi Y; Hishima T; Iwasaki Y; Ishikawa S; Fukayama M
    Virchows Arch; 2012 Oct; 461(4):367-77. PubMed ID: 22915242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis.
    Fang M; Lin Y; Xue C; Sheng K; Guo Z; Han Y; Lin H; Wu Y; Sang Y; Chen X; Howell SB; Lin X; Lin X
    Br J Cancer; 2024 Oct; 131(6):1080-1091. PubMed ID: 39003371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways.
    Du F; Sun L; Chu Y; Li T; Lei C; Wang X; Jiang M; Min Y; Lu Y; Zhao X; Nie Y; Fan D
    Cancer Commun (Lond); 2018 Jul; 38(1):45. PubMed ID: 29976242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
    Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
    PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
    Yamada L; Saito M; Thar Min AK; Saito K; Ashizawa M; Kase K; Nakajima S; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Kono K
    Gastric Cancer; 2021 Jan; 24(1):60-71. PubMed ID: 32506298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A CRISPR/Cas9-Engineered
    Lo YH; Kolahi KS; Du Y; Chang CY; Krokhotin A; Nair A; Sobba WD; Karlsson K; Jones SJ; Longacre TA; Mah AT; Tercan B; Sockell A; Xu H; Seoane JA; Chen J; Shmulevich I; Weissman JS; Curtis C; Califano A; Fu H; Crabtree GR; Kuo CJ
    Cancer Discov; 2021 Jun; 11(6):1562-1581. PubMed ID: 33451982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF.
    Kong F; Deng X; Kong X; Du Y; Li L; Zhu H; Wang Y; Xie D; Guha S; Li Z; Guan M; Xie K
    Oncogene; 2018 Nov; 37(45):5982-5996. PubMed ID: 29985481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive molecular phenotyping of
    Xu C; Huang KK; Law JH; Chua JS; Sheng T; Flores NM; Pizzi MP; Okabe A; Tan ALK; Zhu F; Kumar V; Lu X; Benitez AM; Lian BSX; Ma H; Ho SWT; Ramnarayanan K; Anene-Nzelu CG; Razavi-Mohseni M; Abdul Ghani SAB; Tay ST; Ong X; Lee MH; Guo YA; Ashktorab H; Smoot D; Li S; Skanderup AJ; Beer MA; Foo RSY; Wong JSH; Sanghvi K; Yong WP; Sundar R; Kaneda A; Prabhakar S; Mazur PK; Ajani JA; Yeoh KG; So JB; Tan P;
    Gut; 2023 Sep; 72(9):1651-1663. PubMed ID: 36918265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
    Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
    Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
    Han N; Kim MA; Lee HS; Kim WH
    Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging roles of ARID1A in tumor suppression.
    Wu RC; Wang TL; Shih IeM
    Cancer Biol Ther; 2014 Jun; 15(6):655-64. PubMed ID: 24618703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique characteristics of
    Kim YS; Jeong H; Choi JW; Oh HE; Lee JH
    Saudi J Gastroenterol; 2017; 23(5):268-274. PubMed ID: 28937020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.